Efter att resultaten från Chordate Medicals kliniska studie PM007 presenterades både på American Headache Society Scientific Meeting i USA och på en kongress i Berlin intervjuade Biostock prövningsledaren dr Jan Hoffmann om resultaten och om hur studien mottagits.
”For the attendees, the findings were of great interest as K.O.S is based on an entirely new and non-pharmacological treatment concept. In addition, in contrast to some of the other available neuromodulation techniques, the efficacy of K.O.S was demonstrated by a sham-controlled trial and not just by an open-label study.”